In early 2020 before most people had heard the words “COVID-19” Oxford Biomedica (OXB) were bringing their new viral vector manufacturing suite on-line. As the pandemic started and the world went into lockdown in March, a crisis team planned their response.

 

By the beginning of April, Oxford Biomedica had joined the Oxford University led consortium to develop and manufacture a vaccine alongside Pall Corporation and others.  In December 2020, the ChAdOx1 vaccine was given emergency authorisation by the UK regulatory authorities and is estimated to have saved over 6 million lives in 2021*.

 

What can we learn from this extraordinary time, to help us accelerate process development and scale-up for the many new drugs currently in clinical trials?

 

In this case study webinar, you will hear how Pall and OXB collaborated to develop and scale-up the manufacturing process for the ChAdOx1 COVID-19 vaccine enabling OXB to start manufacturing in less than 6 months. You will hear:

 

  • How standard processes and single-use system designs enable fast deployment
  • How standardisation solved operational and supply-chain challenges
  • How training solutions were provided for more than 100 new operators

 

If you are not available to join the live webcast but are interested in viewing the recording, please register and you will be able to access the content on-demand and in your own time.

 

* https://www.bloomberg.com/news/articles/2022-07-13/astra-s-covid-vaccine-saved-over-six-million-lives-in-first-year

 

Speakers

Hélène Pora

 

VP Technical Communication & Regulatory Strategy,
Pall Corporation

 

Hélène has been instrumental in the development of Pall single-use technologies for the last 20 years, while getting heavily involved in manufacturing, quality and regulatory aspects. She has over 35 years of experience working for the biopharmaceutical industry, the last 30 years within Pall Corporation. She speaks regularly at conferences about single-use technology with a strong focus on validation and overall process integration aspects. She is also involved in different industry interest groups with a strong focus on BioPhorum, and BPSA.

 

Kevin Thompson

 

Senior Technical Director, Pall Advanced Separation Systems (PASS), Pall Corporation

 

Kevin is a Senior Technical Director within the PASS team - a customer-focused process engineering and project management team responsible for delivering integrated solutions to the pharmaceutical industry. He has spent the last 40 years in engineering, starting in the UK’s electrical supply industry, transitioning to oil and gas, followed by chemicals and polymers, with the last 22 years dedicated to pharmaceuticals. He is located within our Center of Excellence in Portsmouth, UK, where he manages a group of project managers - process and commissioning engineers supporting global projects. His team was dedicated to the Astra Zeneca /Oxford COVID-19 vaccine project where their involvement started in the early process development phase with Oxford University, through to delivery and deployment of the process solutions to many CMOs.

 

Mark Woodyer

 

Senior Director, MSAT

Oxford BioMedica (UK) Limited

 

A chartered Biochemical Engineer with over 20 years’ experience within the biopharmaceutical industry, Mark has worked at Oxford Biomedica for the last 7 years.  While there, he has been responsible for management and execution of technology transfer projects from inception to delivery, providing process engineering support for cutting edge new equipment and facilities.  He describes the ChAdOx1 COVID-19 vaccine as the most intense and focused project that he has worked on.